Literature DB >> 8712292

Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group.

P Faria1, J B Beckwith, K Mishra, C Zuppan, D A Weeks, N Breslow, D M Green.   

Abstract

Anaplasia, defined by the presence of extreme nuclear and mitotic atypia, is a potent marker of adverse prognosis in Wilms tumor (WT). Anaplastic WT cells apparently have increased resistance to therapy rather than increased aggressiveness. The distribution of anaplasia should therefore have critical prognostic relevance. The original definitions for focal anaplasia (FA) and diffuse anaplasia (DA) were based on quantitative rather than topographical criteria and lacked prognostic significance. A new definition was developed based on the distribution of anaplastic changes within the tumor: FA applies only to tumors with anaplasia confined to one or a few discrete loci within the primary tumor, with no anaplasia or marked nuclear atypia elsewhere. This revised definition was evaluated in 165 cases with anaplastic WT entered on the third and fourth National Wilms Tumor Study. Only three relapses and one death occurred among 39 cases with FA, regardless of tumor stage, a result comparable to that for nonanaplastic WT. Eight children with metastases at diagnosis and FA in the primary tumor were alive and free of relapse; 22 of 23 children with stage IV DA WT died of tumor. This new definition reinforces the importance of carefully documenting the exact site from which each tumor section is obtained.

Entities:  

Mesh:

Year:  1996        PMID: 8712292     DOI: 10.1097/00000478-199608000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  31 in total

Review 1.  Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol.

Authors:  Marry M van den Heuvel-Eibrink; Janna A Hol; Kathy Pritchard-Jones; Harm van Tinteren; Rhoikos Furtwängler; Arnauld C Verschuur; Gordan M Vujanic; Ivo Leuschner; Jesper Brok; Christian Rübe; Anne M Smets; Geert O Janssens; Jan Godzinski; Gema L Ramírez-Villar; Beatriz de Camargo; Heidi Segers; Paola Collini; Manfred Gessler; Christophe Bergeron; Filippo Spreafico; Norbert Graf
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

2.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

3.  Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.

Authors:  Najat C Daw; Yueh-Yun Chi; Yeonil Kim; Elizabeth A Mullen; John A Kalapurakal; Jing Tian; Geetika Khanna; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Anne B Warwick; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal:  Eur J Cancer       Date:  2019-07-17       Impact factor: 9.162

4.  Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases.

Authors:  Gulisa Turashvili; Daniel J Fix; Robert A Soslow; Kay J Park
Journal:  Int J Gynecol Pathol       Date:  2018-12-03       Impact factor: 2.762

5.  Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor.

Authors:  Andrew J Murphy; Janene Pierce; Christian de Caestecker; Jaime Libes; David Neblett; Mark de Caestecker; Alan O Perantoni; Shunsuke Tanigawa; James R Anderson; Jeffrey S Dome; Amrita Das; Thomas J Carroll; Harold N Lovvorn
Journal:  Pediatr Blood Cancer       Date:  2013-09-20       Impact factor: 3.167

6.  Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.

Authors:  Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn
Journal:  Int J Cancer       Date:  2012-04-04       Impact factor: 7.396

7.  Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.

Authors:  Takaharu Oue; Tsugumichi Koshinaga; Tetsuya Takimoto; Hajime Okita; Yukichi Tanaka; Miwako Nozaki; Masayuki Haruta; Yasuhiko Kaneko; Masahiro Fukuzawa
Journal:  Pediatr Surg Int       Date:  2016-07-29       Impact factor: 1.827

8.  Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Authors:  Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

9.  Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Stephen Qualman; James Lynch; Julia Bridge; David Parham; Lisa Teot; William Meyer; Alberto Pappo
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

Review 10.  Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.

Authors:  Jeffrey S Dome; Norbert Graf; James I Geller; Conrad V Fernandez; Elizabeth A Mullen; Filippo Spreafico; Marry Van den Heuvel-Eibrink; Kathy Pritchard-Jones
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.